Rheumatology News This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 24.

Psoriasis, Bladder Cancer, and Fever: What's the Connection?Psoriasis, Bladder Cancer, and Fever: What's the Connection?
Dr. Jon Kay discusses an interesting case of a 55-year-old man previously treated for bladder cancer and psoriasis who is now presenting with fever and night sweats. Medscape Rheumatology
Source: Medscape Today Headlines - June 8, 2012 Category: Consumer Health News Tags: Rheumatology Commentary Source Type: news

Early Menopause Linked to Milder Rheumatoid ArthritisEarly Menopause Linked to Milder Rheumatoid Arthritis
Although early menopause increases the risk for rheumatoid arthritis, new research suggests that is a milder form of the disease. Medscape Medical News
Source: Medscape Today Headlines - June 8, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

IL-17 Blocker Shows Promise in Arthritis Trial (CME/CE)
BERLIN (MedPage Today) -- Interleukin-17 is again looking like an attractive drug target in rheumatoid arthritis, as a monoclonal antibody against the cytokine showed good results in a phase II trial reported here.
Source: MedPage Today Primary Care - June 8, 2012 Category: Primary Care Source Type: news

Stem Cell Transplantation Shows Promise in SclerodermaStem Cell Transplantation Shows Promise in Scleroderma
Autologous stem cell transplantation increased long-term survival in patients with early diffuse cutaneous systemic sclerosis in a phase 3 study. Medscape Medical News
Source: Medscape Today Headlines - June 8, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Cimzia Succeeds in Psoriatic Arthritis (CME/CE)
BERLIN (MedPage Today) -- Response rates to the tumor necrosis factor inhibitor certolizumab pegol among patients with active psoriatic arthritis were twice those seen with placebo in a phase III study, a researcher said here.
Source: MedPage Today Rheumatology - June 8, 2012 Category: Rheumatology Source Type: news

ChemoCentryx Announces Peer-Reviewed Publication of Positive Phase 2 Clinical Data with CCX354, a Novel Inhibitor of Chemokine Receptor CCR1 in Patients with Rheumatoid Arthritis
MOUNTAIN VIEW, Calif., June 8, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today publication of positive data from the Company's Phase 2 CARAT-2 study for CCX354, a potent and selective, orally-administered inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA). The findings showed that CCX354 was generally well tolerated by patients with RA. Measurement of evidence of clinical activity included the ACR20 response at Week 12 in patients who met trial inclusion criteria at the start of dosing (Day 1 eligible...
Source: Medical News (via PRIMEZONE) - June 8, 2012 Category: Pharmaceuticals Source Type: news

Rheumatoid Arthritis Patients Benefit From Personalizing Biologic Treatment And It Is Also Cost-Effective
Data presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by 2,595,557 euros per 272 patients over 3 years (95 percentile range -2,983,760 to -2,211,755 euros), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs)*. Cost savings were mostly on drug costs...
Source: Health News from Medical News Today - June 8, 2012 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news

Study: Actemra Tops Rival in Rheumatoid Arthritis
Title: Study: Actemra Tops Rival in Rheumatoid ArthritisCategory: Health NewsCreated: 6/8/2012 11:00:00 AMLast Editorial Review: 6/8/2012 12:00:00 AM
Source: MedicineNet Arthritis General - June 8, 2012 Category: Rheumatology Source Type: news

Two-Thirds of Osteo Hip Fractures Occur After 80: U.S. Study
Title: Two-Thirds of Osteo Hip Fractures Occur After 80: U.S. StudyCategory: Health NewsCreated: 6/7/2012 6:05:00 PMLast Editorial Review: 6/8/2012 12:00:00 AM
Source: MedicineNet Arthritis General - June 8, 2012 Category: Rheumatology Source Type: news

Access To Biologics For Arthritis Not Provided By Almost One-Quarter Of European Countries
Data from a study presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates the vast inequalities in access to biologics for the treatments of rheumatoid arthritis (RA) across 46 European countries, with 22% (n=10) of countries having no biologic reimbursed at all. In the 36 countries with reimbursed biologics, only 27 had more than five biologics reimbursed. The number of reimbursed drugs showed a moderate to very strong correlation with economic welfare and an inverse correlation with RA health status...
Source: Health News from Medical News Today - June 8, 2012 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news

For Reducing Signs And Symptoms Of Rheumatoid Arthritis, Tocilizumab More Effective Than Adalimumab
Data presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28* (-3.3 vs. -1.8, p "Approximately one third of patients with rheumatoid arthritis receive biologic monotherapy and this is the first head-to-head trial comparing an IL-6 inhibitor to an anti-TNF, two therapies with different modes of action," said Professor Cem Gabay from University Hospitals of Geneva, Switzerland...
Source: Health News from Medical News Today - June 8, 2012 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news

Rheumatoid arthritis drug has added benefits
Treatment with anti-tumor necrosis factor drugs reduces the risk for cardiovascular events in patients with rheumatoid arthritis, researchers report.
Source: MedWire News - Cardiology - June 8, 2012 Category: Cardiology Source Type: news

Conference report: Phase 3 data show ustekinumab (Stelara®) reduced signs and symptoms of active psoriatic arthritis - PSUMMIT I study
Source: BioSpace.com Area: News Data presented at the European League Against Rheumatism (EULAR) Annual Congress 2012 suggest that patients with active psoriatic arthritis (PsA) receiving the interleukin (IL)-12/23 inhibitor ustekinumab (Stelara®) experienced significant improvements in signs and symptoms of the disease. The study was designed as a phase 3, multicentre, double-blind, placebo-controlled study including 615 adults with PsA. The study included patients diagnosed with active PsA who had at least five tender and five swollen joints and CRP levels of at least 0.3 mg/dL despite treatment with DMARDs ...
Source: NeLM - News - June 8, 2012 Category: Drugs & Pharmacology Source Type: news

Conference report: Phase 3 study results for investigational use of adalimumab in patients with active peripheral spondyloarthritis
Source: BioSpace Area: News The results of an ongoing phase 3, randomised controlled study of adalimumab in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) have been presented at the European League Against Rheumatism (EULAR) 2012 Congress. PSpA is characterised by peripheral arthritis (asymmetric, lower limb or both), enthesitis (painful inflammation where a tendon or ligament attaches to bone) or dactylitis (a painful and swollen digit), in addition to the presence of other features (family history of SpA, history of infl...
Source: NeLM - News - June 8, 2012 Category: Drugs & Pharmacology Source Type: news

Conference report: 10-year data presented evaluating adalimumab for patients with long-standing moderate-to-severe rheumatoid arthritis
Source: BioSpace Area: News The results of two long-term, open label studies (DE019 and DE020) investigating the results of adalimumab treatment for up to 10 years in patients with long-standing, moderate-to-severe rheumatoid arthritis (RA) have been presented at the European League Against Rheumatism (EULAR) 2012 Congress. In both studies, patients were assessed for improvements in signs and symptoms of RA, such as joint pain, swelling and stiffness, as well as physical function and achievement of clinical remission. Follow up to 10 years of adalimumab therapy showed that patients in the studies continued to maintain im...
Source: NeLM - News - June 8, 2012 Category: Drugs & Pharmacology Source Type: news

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus
Source: Arthritis and Rheumatism Area: News This paper reports the results of an ongoing open-label phase 2 study which was designed to assess the safety profile of belimumab over 4 years of exposure in combination with standard therapy in patients with active systemic lupus erythematosus (SLE). The initial study recruited patients with active SLE in a double-blind, placebo-controlled, randomised 52-week trial of intravenous belimumab (1, 4, and 10 mg/kg; administered on days 0, 14, and 28 and then every 28 days) plus standard therapy (such as corticosteroids, antimalarials, and immunosuppressant drugs), alone ...
Source: NeLM - News - June 8, 2012 Category: Drugs & Pharmacology Source Type: news

Conference report: Abatacept (Orencia®) demonstrates comparable efficacy to adalimumab (Humira®) in patients with moderate to severe rheumatoid arthritis in head-to-head study - AMPLE study
Source: PharmaLive Area: News PharmaLive reports on data presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology relating to a head-to-head study comparing abatacept to adalimumab in biologic naïve patients with moderate to severe rheumatoid arthritis (RA) on background methotrexate. The AMPLE study is a phase IIIb, randomised, investigator-blinded multinational study of 24 months duration with a 12 month efficacy primary endpoint (non-inferiority for American College of Rheumatology criteria of 20 percent [ACR20]). The study included 646 adult biologic-naïve patie...
Source: NeLM - News - June 8, 2012 Category: Drugs & Pharmacology Source Type: news

Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo
(European League Against Rheumatism) A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than twice as likely to achieve the study's primary endpoint, ACR20* at 24 weeks, than those treated with placebo (49.5 pecent vs. 22.8percent). 42.4 percent of patients treated with UST 45mg were also more likely to achieve ACR20 at 24 weeks compared to placebo.
Source: EurekAlert! - Medicine and Health - June 8, 2012 Category: Global & Universal Source Type: news

76 percent of patients on oral JAK1/JAK2 inhibitor plus DMARDS achieve ACR20 response at week 12
(European League Against Rheumatism) Data from a Phase IIb study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, show that 76 percent of patients with active rheumatoid arthritis receiving either four mg or eight mg of baricitinib, an oral JAK1/JAK2 inhibitor, plus stable methotrexate achieved ACR20* response compared with 41 percent of placebo-treated patients at 12 weeks.
Source: EurekAlert! - Social and Behavioral Science - June 8, 2012 Category: Global & Universal Source Type: news

Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis
(European League Against Rheumatism) A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs.
Source: EurekAlert! - Social and Behavioral Science - June 8, 2012 Category: Global & Universal Source Type: news

Lung changes are present in nearly half of ACPA positive RA patients at disease onset
(European League Against Rheumatism) A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that lung changes in association with anti-citrullinated protein autoantibody (ACPA) status are a primary manifestation of rheumatoid arthritis (RA).
Source: EurekAlert! - Social and Behavioral Science - June 8, 2012 Category: Global & Universal Source Type: news

Obesity negatively predicts minimal disease activity achievement in patients with PSA
(European League Against Rheumatism) According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet.
Source: EurekAlert! - Social and Behavioral Science - June 8, 2012 Category: Global & Universal Source Type: news

Early menopause predicts a milder form of rheumatoid arthritis
(European League Against Rheumatism) A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that early menopause predicts a milder form of rheumatoid arthritis (RA). New insights on factors influencing RA are good news for sufferers of the chronic inflammatory disease that currently affects over 2 million women in Europe.
Source: EurekAlert! - Social and Behavioral Science - June 8, 2012 Category: Global & Universal Source Type: news

Rabbit risk score can help rheumatologists identify patients at high risk of infection
(European League Against Rheumatism) Results of a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, suggest that the newly developed RABBIT Risk Score, which calculates the risk of serious infections in patients with rheumatoid arthritis (RA) who are treated with anti-tumour necrosis factor drugs (anti-TNFs) or conventional disease modifying anti-rheumatic drugs (DMARDs) is a valid and effective tool for rheumatologists to predict risk of serious infection.
Source: EurekAlert! - Social and Behavioral Science - June 8, 2012 Category: Global & Universal Source Type: news

Two-Thirds of Osteo Hip Fractures Occur After 80: U.S. Study
Researchers urge greater push to diagnose, prevent, treat osteoporosis in extreme elderly
Source: The Doctors Lounge - Health News - June 7, 2012 Category: Consumer Health News Authors: webmaster at doctorslounge.com Tags: Family Medicine, Geriatrics, Nursing, Orthopedics, Rheumatology, News, Source Type: news

Tocilizumab Beats Adalimumab for RA: ADACTA TrialTocilizumab Beats Adalimumab for RA: ADACTA Trial
Monotherapy with tocilizumab showed efficacy superior to that of monotherapy with adalimumab in reducing signs and symptoms of rheumatoid arthritis. Medscape Medical News
Source: Medscape Today Headlines - June 7, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Dead Heat in RA Biologics Trial (CME/CE)
BERLIN (MedPage Today) -- No meaningful differences in efficacy or safety were seen in a head-to-head trial of injectable abatacept (Orencia) versus adalimumab (Humira) in rheumatoid arthritis, a researcher said here.
Source: MedPage Today Primary Care - June 7, 2012 Category: Primary Care Source Type: news

Serum Biomarkers Predict Ankylosing Spondylitis Progression Serum Biomarkers Predict Ankylosing Spondylitis Progression
Research has shown for the first time that serum biomarkers can predict the progression of ankylosing spondylitis in patients already at high risk for progression. Medscape Medical News
Source: Medscape Today Headlines - June 7, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Argos Therapeutics Presents Positive Phase 1a Data for AGS-009 in Patients With Lupus at 2012 EULAR Congress
DURHAM, N.C., June 7, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized and novel immunotherapies, presented positive Phase 1a clinical data for its monoclonal antibody-based therapy, AGS-009, for the treatment of systemic lupus erythematosus (lupus) at the 2012 European League Against Rheumatism (EULAR) Congress in Berlin.
Source: Medical News (via PRIMEZONE) - June 7, 2012 Category: Pharmaceuticals Source Type: news

Study: Actemra Tops Rival in Rheumatoid Arthritis
A new study shows that the drug Actemra may be a more effective treatment for rheumatoid arthritis than the drug Humira when the medications are used by themselves.
Source: WebMD Health - June 7, 2012 Category: Consumer Health News Source Type: news

Conference data: Canakinumab for systemic juvenile idiopathic arthritis and TNF receptor-associated periodic syndrome (TRAPS)
Source: PharmaLive Area: News Novartis has announced new data from two trials with canakinumab (ACZ885): a pivotal phase III study in patients with systemic juvenile idiopathic arthritis (SJIA), and a phase II study in patients with tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS). Both studies met their primary endpoints, and the results will be presented at the annual congress of the European League Against Rheumatism (EULAR 2012). SJIA is a rare systemic interleukin-1 beta (IL-1 beta)-mediated autoinflammatory disease characterised by daily spiking fevers, rash, chronic pai...
Source: NeLM - News - June 7, 2012 Category: Drugs & Pharmacology Source Type: news

Horizon scanning: post hoc data on efficacy and safety of pegloticase (Krystexxa®) in patients with chronic gout and kidney disease at any stage presented at conference
Source: BioSpace Area: News Savient Pharmaceuticals, Inc. has announced that new data presented in an oral session at the European League Against Rheumatism (EULAR) 2012 congress showed that patients with refractory chronic gout (RCG) who also have chronic kidney disease (CKD) responded to treatment with pegloticase (Krystexxa®), regardless of baseline CKD stage. Pegloticase is a PEGylated uric acid specific enzyme for administration by intravenous infusion for the treatment of RCG in adult patients. This post-hoc analysis evaluated over 200 patients with CKD stages 1 to 4 (n=34, 74, 80, 23, respectively) who...
Source: NeLM - News - June 7, 2012 Category: Drugs & Pharmacology Source Type: news

Data from phase IV ADACTA study indicate better DAS28 score with tocilizumab versus adalimumab in rheumatoid arthritis
Source: BioSpace Area: News Genentech has announced data from the ADACTA study, a phase IV multicentre, randomised, double blinded, parallel group study comparing the reduction in signs and symptoms during monotherapy treatment with tocilizumab versus adalimumab in adult patients with severe active rheumatoid arthritis (RA) who either have intolerance to methotrexate (MTX) or in whom continued MTX treatment is inappropriate. These patients had not previously received a biologic medicine for RA. The study involved 326 patients randomised to receive tocilizumab 8 mg/kg IV every four weeks (plus placebo adalimuma...
Source: NeLM - News - June 7, 2012 Category: Drugs & Pharmacology Source Type: news

Obesity, Diabetes May Raise Complications After Joint Replacement
Lung disease can also put older hip and knee surgery patients at risk, study finds
Source: Rheumatology News - Doctors Lounge - June 7, 2012 Category: Rheumatology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Nursing, Rheumatology, Surgery, News, Source Type: news

Treatment with anti-TNFs reduces the risk of cardiovascular events in rheumatoid arthritis
(European League Against Rheumatism) Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumor necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24 percent, 42 percent and 56 percent in patients with rheumatoid arthritis respectively.
Source: EurekAlert! - Medicine and Health - June 7, 2012 Category: Global & Universal Source Type: news

Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
(European League Against Rheumatism) Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis can reduce total costs by 2,595,557 per 272 patients over three years (95 percentile range -2,983,760 to -2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years.
Source: EurekAlert! - Medicine and Health - June 7, 2012 Category: Global & Universal Source Type: news

Patients taking certolizumab pegol are twice as likely to achievE ACR20 compared to placebo
(European League Against Rheumatism) A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20 response at week 12 than those on placebo: 58 percent on CZP200mg Q2W; and 51.9 percent on CZP 400 mg Q4W compared to 24.3 percent on placebo.
Source: EurekAlert! - Medicine and Health - June 7, 2012 Category: Global & Universal Source Type: news

Control of disease activity and biologic treatment increase life expectency in RA patients
(European League Against Rheumatism) According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis who are prescribed biologic treatments have a significantly lower mortality risk than those just treated with traditional disease modifying anti-rheumatic drugs.
Source: EurekAlert! - Medicine and Health - June 7, 2012 Category: Global & Universal Source Type: news

Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab
(European League Against Rheumatism) Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8 percent of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20.
Source: EurekAlert! - Medicine and Health - June 7, 2012 Category: Global & Universal Source Type: news

Nearly two-thirds of American osteoporotic hip fractures are seen in the extreme elderly
(European League Against Rheumatism) A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
Source: EurekAlert! - Social and Behavioral Science - June 7, 2012 Category: Global & Universal Source Type: news

Treatment with anti-TNFs can increase the risk of shingles by up to 75 percent
(European League Against Rheumatism) Patients with inflammatory rheumatic diseases treated with anti-tumor necrosis factor medications (anti-TNFs) have a 75 percent greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs, according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.
Source: EurekAlert! - Social and Behavioral Science - June 7, 2012 Category: Global & Universal Source Type: news

Haematopoietic stem cell transplantation increases survival in systemic sclerosis patients
(European League Against Rheumatism) Initial results from an international, investigator-initiated, open label phase III trial were presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism. Data indicate that haematopoietic stem cell transplantation results in better long term survival than conventional treatment for patients with poor prognosis early diffuse cutaneous systemic sclerosis.
Source: EurekAlert! - Social and Behavioral Science - June 7, 2012 Category: Global & Universal Source Type: news

Medical and Patient Groups Ally on Musculoskeletal HealthMedical and Patient Groups Ally on Musculoskeletal Health
European rheumatologists, orthopaedic surgeons, and patients with arthritis have joined forces in an effort to improve political and public support for musculoskeletal disease. Medscape Medical News
Source: Medscape Medical News Headlines - June 6, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Bristol-Myers AMPLE study meets primary end point
Bristol-Myers Squibb has announced results from a head-to-head clinical trial in which Orencia (abatacept) demonstrated comparable efficacy to Humira (adalimumab) in patients with moderate to severe rheumatoid arthritis (RA).
Source: Drug Development Technology - June 6, 2012 Category: Pharmaceuticals Source Type: news

Access to RA Medications Varies Across EuropeAccess to RA Medications Varies Across Europe
There is significant variation in access to reimbursed biologic therapy for rheumatoid arthritis (RA) across Europe, resulting in inequality and inconsistent care, researchers report. Medscape Medical News
Source: Medscape Today Headlines - June 6, 2012 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Actemra Tops Humira as RA Monotherapy (CME/CE)
BERLIN (MedPage Today) -- The interleukin-6 receptor blocker tocilizumab (Actemra) was significantly more effective as sole treatment for rheumatoid arthritis than adalimumab (Humira) in a head-to-head study.
Source: MedPage Today Geriatrics - June 6, 2012 Category: Geriatrics Source Type: news

European League Against Rheumatism (EULAR) Congress 2012European League Against Rheumatism (EULAR) Congress 2012
Read clinically focused news coverage of key developments from EULAR 2012. Medscape Rheumatology
Source: Medscape Today Headlines - June 6, 2012 Category: Consumer Health News Tags: Conference Coverage Source Type: news

Ultrasounds Spot Heart Disease Early in Rheumatoid Arthritis Patients
Special echocardiograms show promise for early detection of a potentially deadly complication in rheumatoid arthritis: heart disease, Mayo Clinic research shows.
Source: Mayo Clinic Rochester News - June 6, 2012 Category: Hospital Management Authors: Mayo Clinic Source Type: news

Ultrasound May Detect Heart Disease Earlier in Arthritis Patients
Study suggests common diagnostic methods underestimate risk for those with rheumatoid arthritis
Source: The Doctors Lounge - Cardiology - June 6, 2012 Category: Cardiology Authors: webmaster at doctorslounge.com Tags: Cardiology, Radiology, Rheumatology, News, Source Type: news